Pandemic Planning

home
home

Email This Page   |   Print This Page   |   Site Map   |   Search


ORDERING RELENZA

How to Order RELENZA

It’s critical that you stockpile enough antiviral to sustain your organization during the course of the pandemic. You need to consider the number of employees to cover, any family members, outside support staff and vendors, as well as the duration and number of pandemic waves that may occur. In any given geographic region, each wave could last 3 to 5 months, and a second wave could appear anywhere from 1 to 3 months after the first disappears.[37]

Use the following guidelines to help determine the correct amount of RELENZA to order for your organization.

Guideline 1: Employee Coverage
Guideline 2: Calculate Number of RELENZA ROTADISKs® to Order
Guideline 3: Placing An Order
Guideline 4: Storage
Guideline 5: Distribution
Guideline 6: Education

Guideline 1: Employee Coverage

 
Important Safety Information About RELENZA

RELENZA IS NOT RECOMMENDED FOR TREATMENT OR PROPHYLAXIS OF INFLUENZA IN INDIVIDUALS WITH UNDERLYING AIRWAY DISEASE (SUCH AS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE).
  • Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  • RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  • Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  • Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  • If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  • Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  • Please see complete Prescribing Information for RELENZA



This site is intended for US residents only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us

 

home